MedCity News October 14, 2021
Biotech startup Tentarix Biotherapeutics has come out of stealth with $50 million and technology that develops biologic drugs endowed with multiple functions. The company aims to develop new multispecific biologic drugs for cancer and autoimmune diseases.
The biologic drugs currently available are designed to hit one or two targets, but even so, they can still activate other cells and spark adverse effects. Tentarix Biotherapeutics is developing biologic drugs that selectively hit multiple targets in a manner that avoids activating immune cells and causing problems. The biotech startup aims to use its approach to develop new treatments for cancer and autoimmune diseases, and it has emerged with $50 million in funding.
The Series A financing announced Thursday was co-led by Versant...
Today's Sponsors
Today's Sponsor